Cytokines, platelet production and hemostasis

Platelets

Volumn 8, Issue 2-3, 1997, Pages 93-104

  Burstein, S A ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HEMOPOIETIC GROWTH FACTOR;

ATHEROGENESIS; BLEEDING; HEMOSTASIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOGENESIS;

EID: 0030760353     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109777348     Document Type: Review

References (179)

1. Gewirtz AM. Megakaryocytopoiesis: The state of the art. Thromb Haemost 1995; 74: 204-9.
2. Burstein SA, Breton-Gorius J. Megakaryopoiesis and platelet formation. InL Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology. New York: McGraw-Hill, 1995: 1149-61.
3. Briddell RA, Brandt JE, Straneva JE, Srour EF, Hoffman R. Characterization of the human burst-forming unit-megakaryocyte. Blood 1989; 74: 145-51.
4. Long MW, Heffner CH, Gragowski LL. In vitro differences in responsiveness of early (BFU-Mk) and late (CFU-Mk) murine megakaryocyte progenitor cells. Prog Clin Biol Res 1986; 215: 179-86.
5. Debili N, Coulombel L, Croisille L, Katz A, Guichard J, Breton-Gorius J, Vainchenker W. Characterization of a bipotent erythromegakaryocytic progenitor in human bone marrow. Blood 1996; 88: 1284-96.
6. Fauser AA, Messner HA. Identification of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neutrophils, granulocytes and erythroblasts. Blood 1979; 53: 1023-7.
7. Debili N, Issaad C, Masse JM, Guichard J, Katz A, Breton-Gorius J, Vainchenker W. Expression of CD34 and platelet glycoproteins during human megakaryocytic differentiation. Blood 1992; 80: 3022-35.
8. Long MW, Williams N. Immature megakaryocytes in the mouse: Physical characteristics, cell cycle status and in vitro responsiveness to thrombopoietic stimulating factor. Blood 1982; 59: 569-75.
9. Rabellino EM, Levene RB, Leung LLK, Nachman RL. Human megakaryocytes II. Expression of platelet proteins in early marrow megakaryocytes. J Exp Med 1981; 154: 88-100.
10. Thompson A, Zhang Y, Kamen D, Jackson CW, Cardiff RD, Ravid K. Deregulated expression of c-myc in megakaryocytes of transgenic mice increases megakaryopoiesis and decreases polyploidization. J Biol Chem 1996; 271: 22976-82.
11. Choi ES, Nicheol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85: 402-13.
12. Leven RM. Differential regulation of integrin-mediated proplatelet formation and megakaryocyte spreading. J Cell Physiol 1995; 163: 597-607.
13. Hoffman R. Regulation of megakaryocytopoiesis. Blood 1989; 74: 1196-212.
14. Kaushansky K. Thrombopoietin. The primary regulator of platelet production. Blood 1995; 86: 419-31.
15. Debili N, Wendung F, Cosman D, Titeux M, Florindo C, Dusanter-Fourt I, Schooley K, Methia N, Charon M, Nador R, Bettaieb A, Vainchenker W. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995; 85: 391-401.
16. Vainchenker W, Methia N, Debili N, Titeux M, Wendling F. C-mpl, the thrombopoietin receptor. Thromb Haemost 1995; 74: 526-8.
17. Nichol JL, Hokom MM, Hornkohl A, Sheridan WP, Ohashi H, Kato T, Li YS, Bartley TD, Choi E, Bogenberger J, Skrine JD, Knudten A, Chen J, Trail G, Sleeman L, Cole S, Grampp G, Hunt P. Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995; 95: 2973-8.
18. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombo-poietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85: 2720-30.
19. McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995; 86: 3668-75.
20. Cohen-Solal K, Villeval JL, Titeux M, Lok S, Vainchenker W, Wendling F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996; 88: 2578-84.
21. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 11104-8.
22. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87: 567-73.
23. Gurney AL, Carver-Moore K, De Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265: 1445-7.
24. Carver-Moore K, Broxmeyer HE, Luoh SM, Cooper S, Peng JP, Burstein SA, Moore MW, De Sauvage FJ. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood 1996; 88: 803-8.
25. Li J, Xia Y, Kuter DJ. Analysis of the thrombopoietin receptor (mpl) on platelets from normal and thrombocythemic patients. Blood 1996; 88(Suppl 1): 545a (Abstract).
26. Hollen CW, Henthorn J, Koziol J, Burstein SA. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol 1991; 79: 286-90.
27. Blay J-Y, Favrot M, Rossi J-F, Wijdenes J. Role of interleukin-6 in paraneoplastic thrombocytosis. Blood 1993; 82: 2261-2.
28. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH, Rubin SC. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 1993; 83: 433-41.
29. Kimura H, Ishibashi T, Shikama Y, Okano A, Akiyama Y, Uchida T, Maruyama Y. Interleukin-1B (IL-1β) induces thrombocytosis in mice: possible implication of IL-6. Blood 1990; 76: 2493-500.
30. Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, Zucker-Franklin D, Lofton-Day C. Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995; 92: 3234-8.
31. Broudy VC, Lin NL, Fox N, Taga T, Saito M, Kaushansky K. Thrombopoietin stimulates colony-forming unit megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. Blood 1996; 88: 2026-32.
32. Harker LA, Hunt P, Marzec UM, Kelly AB, Tomer A, Hanson SR, Stead RB. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87: 1833-44.
33. Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88: 511-21.
34. Ulich TR, Del Castillo J, Yin S, Swift S, Padilla D, Denaldi G, Bennett L, Shutter J, Bogenberger J, Sun D, Samal B, Shimamoto G, Lee R, Steinbrink R, Boone T, Sheridan WT, Hunt P. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86: 971-6.
35. Hokom MM, Lacey D, Kinstler OB, Choi E, Kaufman S, Faust J, Rowan C, Dwyer E, Nichol JL, Grasel T, Wilson J, Steinbrink R, Hecht R, Winters D, Boone T, Hunt P. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86: 4486-92.
36. Farese AM, Hunt P, Boone T, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995; 86: 54-9.
37. Fibbe WE, Heemskerk DPM, Laterveer L, Pruijt JFM, Foster D, Kaushansky K, Willemze R. Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 1995; 86: 3308-13.
38. Basser R, Rasko J, Clarke K, Green M, Cebon J, Grigg A. Berndt M, Zalcberg J, Marty J, Menchaca D, Tomita D, Fox R, Begley G. Pegylated megakaryocyte growth and development factor (PEG-rHumGDF) enhances the mobilization of peripheral blood progenitor cells (PBPC) by chemotherapy and filgastim. Blood 1996; 88(Suppl 1): 641a (Abstract).
39. Archimbaud E, Ottmann O, Liu Yin JA, Lechner K, Dombret H, Sanz MA, Herrmann F, Gruss H, Fenaux P, Ganser A, Heil G, Kanz L, Brugger W, Sims T, Olsen K, Hoelzer D. A randomised, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de-novo acute myeloid leukemia (AML): early results. Blood 1996; 88(Suppl 1): 447a (Abstract).
40. Basser R, Clarke K, Fox R, Green M, Cebon J, Marty J, Menchaca D, Tomita D, Begley G. Randomized, double-blind, placebo-controlled phase I trial of pegylated megakaryocyte growth and development factor (PEG-rHuMGDF) administered to patients with advanced cancer before and after chemotherapy - early results. Blood 1995; 86 (Suppl 1): 257a (Abstract).
41. + cells in a serum-free system. Br J Haematol 1996; 93: 13-17.
42. Avraham H, Vannier E, Cowley S, Jiang S, Chi S, Dinarello CA, Zsebo KM, Groopman JE. Effects of the stem cell factor, c-kit ligand, on human megakaryocytic cells. Blood 1992; 79: 365-71.
43. Briddell RA, Bruno E, Cooper RJ, Brandt JE, Hoffman R. Effect of c-kit ligand on in vitro human megakaryocytopoiesis. Blood 1991; 78: 2854-9.
44. Andrews RG, Knitter GH, Bartelmez SH, Langley KE, Farrar D, Hendren RW, Appelbaum FR, Bernstein ID, Zsebo KM. Recombinant human stem cell factor, a c-kit ligand, stimulates hematopoiesis in primates. Blood 1991; 78: 1975-80.
45. Andrews RG, Bensinger WI, Knitter GH, Bartelmez SH, Longin K, Bernstein ID, Appelbaum FR, Zsebo KM. The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons. Blood 1992; 80: 2715-20.
46. Bruno E, Cooper RJ, Briddell RA, Hoffman R. Further examination of the effects of recombinant cytokines on the proliferation of human megakaryocyte progenitor cells. Blood 1991; 77: 2339-46.
47. Carrington PA, Hill RJ, Stenberg PE, Levin J, Corash L, Schreurs J, Baker G, Levin FC. Multiple in vivo effects of interleukin-3 and interleukin-6 on murine megakaryocytopoiesis. Blood 1991; 77: 34-41.
48. Stahl CP, Winton EF, Monroe MC, Haff E, Holman RC, Myers L, Liehl E, Evatt BL. Differential effects of sequential, simultaneous, and single agent interleukin-3 and granulocyte-macrophage colony-stimulating factor on megakaryocyte maturation and platelet response in primates. Blood 1992; 80: 2479-85.
49. Hoffman R. Interleukin-3: A potentially useful agent for treating chemotherapy-related thrombocytopenia. J Clin Oncol 1993; 11: 2057-60.
50. D'Hondt V, Weynants P, Humblet Y, Guillaume T, Canon J-L, Beaudin M, Duprez P, Longueville J, Müll R, Chatelain C, Symann M. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study. J Clin Oncol 1993; 11: 2063-71.
51. Ganser A, Lindemann A, Seipelt G, Ottmann OG, Herrmann F, Eder M, Frisch J, Schulz G, Mertelsmann R, Hoelzer D. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990; 76: 666-76.
52. Lindemann A, Ganser A, Herrmann F, Frisch J, Seipelt G, Schulz G, Hoelzer D, Mertelsmann R. Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 1991; 9: 2120-7.
53. Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 1991; 9: 1241-50.
54. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Maruyama Y. Effect of recombinant granulocyte-macrophage colony-stimulating factor on murine thrombocytopoiesis in vitro and in vivo. Blood 1990; 75: 1433-8.
55. Blazar BR, Kersey JH, McGlave PB, Vallera DA, Lasky LC, Haake RJ, Bostrom B, Weisdorf DR, Epstein C, Ramsay NKC. In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 1989; 73: 849-57.
56. Demetri GD, Antman KHS. Granulocyte-macrophage colony-stimulating factor (GM-CSF): Preclinical and clinical investigations. Semin Oncol 1992; 19: 362-85.
57. Vesole D, Jagannath S, Glenn L, Barlogie B. Effect of low-dose granulocyte-macrophage colony-stimulating factor (LD-GM-CSF) on platelet transfusion-dependent thrombocytopenia. Am J Hematol 1994; 47: 203-7.
58. Tomer A, Stahl CP, McClure HM, Anderson DC, Myers LA, Liehl E, Winton EF. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on platelet survival and activation using a nonhuman primate model. Exp Hematol 1993; 21: 1577-82.
59. Nash RA, Burstein SA, Storb R, Yang WJ, Abrams K, Appelbaum FR, Boone T, Deeg HJ, Durack LD, Schuening FG, McDonough S, Moore P, Nelp WB, Slichter S. Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: Increased destruction of circulating platelets. Blood 1995; 86: 1765-75.
60. Aziz K, Cawley JC, Kamiguti AS, Zuzel M. Degradation of platelet glycoprotein Ibby elastase released from primed neutrophils. Br J Haematol 1995; 91: 46-54.
61. Guinan EC, Lee YS, Lopez KD, Kohler S, Oette DH, Bruno E, Kozakewich H, Nathan DG, Hoffman R. Effects of interleukin-3 and granulocyte-macrophage colony stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood 1993; 81: 1691-8.
62. Vadhan-Raj S. PIXY321 (GM-CSF/IL-34 fusion protein): biology and early clinical development. Stem Cells 1994; 12: 261.
63. Williams DE, Dunn JT, Park LS, Frieden EA, Seiler FR, Farese AM, MacVittie TJ. A GM-CSF/IL-3 fusion protein promotes neutrophil and platelet recovery in sublethally irradiated rhesus monkeys. Biotechnol Therapeut 1993; 4: 17-29.
64. Kishimoto T, Tanaka T, Yoshida K, Akira S, Taga T. Cytokine signal transduction through a homo- or heterodimer of gp130. Ann NY Acad Sci 1995; 766: 224-34.
65. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243-54.
66. Taga T, Kishimoto T. Role of a two-chain IL-6 receptor system in immune and hematopoietic cell regulation. Crit Rev Immunol 1992; 11: 265-80.
67. Ishibashi T, Kimura H, Uchida T, Kariyone S, Friese P, Burstein SA. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 1989; 86: 5953-7.
68. Kimura H, Ishibashi T, Uchida T, Maruyama Y, Friese P, Burstein SA. Interleukin 6 is a differentiation factor for human mega-karyocytes in vitro. Eur J Immunol 1990; 20: 1927-31.
69. Navarro S, Debili N, Le Couedic JP, Klein B, Breton-Gorius J, Doly J, Vainchenker W. Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endoreplication. Blood 1991; 77: 461-71.
70. Stahl CP, Zucker-Franklin D, Evatt BL, Winton EF. Effects of human interleukin-6 on megakaryocyte development and thrombocytopoiesis in primates. Blood 1991; 78: 1467-75.
71. Zeidler C, Kanz L, Hurkuck F, Rittmann KL, Wildfang I, Kadoya T, Mikayama T, Souza L, Weite K. In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates. Blood 1992; 80: 2740-5.
72. Geissler K, Valent P, Bettelheim P, Sillaber C, Wagner B, Kyrie P, Hinterberger W, Lechner K, Liehl E, Mayer P. In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. Blood 1992; 79: 1155-60.
73. D'Hondt V, Humblet Y, Guillaume T, Baatout S, Chatelain C, Berlière M, Longueville J, Feyens AM, De Greve J, Van Oosterom A, Von Graffenried B, Donnez J, Symann M. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: A multi-centric placebo-controlled, randomized phase Ib study. Blood 1995; 85: 2347-53.
74. Crawford J, George M. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy. Semin Oncol 1995; 22(Suppl 7): 18-22.
75. Du XX, Williams DA. Interleukin-11: A multifunctional growth factor derived from the hematopoietic microenvironment. Blood 1994; 83: 2023-30.
76. Weich NS, Wang A, Fitzgerald M, Giannotti J, Yetz-Aldape J, Leven RM, Turner KJ. Interleukin-11 receptor expression in megakaryocytes. Blood 1996; 88(Suppl 1): 60a (Abstract).
77. Musashi M, Yang YC, Paul SR, Clark SC, Sudo T, Ogawa M. Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci USA 1991; 88: 765-9.
78. Bruno E, Briddell RA, Cooper RJ, Hoffman R. Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. Exp Hematol 1991; 19: 378-81.
79. Burstein SA, Mei RL, Henthorn J, Friese P, Turner K. Leukemia inhibitory factor and interleukin-11 promote megakaryoytic maturation in vitro. J Cell Physiol 1992; 153: 305-12.
80. Orazi A, Cooper RJ, Tong J, Gordon MS, Battiato L, Sledge GW, Jr, Kaye JA, Kahsai M, Hoffman R. Effects of recombinant human interleukin-11 (Neumega(TM) rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. Exp Hematol 1996; 24: 1289-97.
81. Neben TY, Loebelenz J, Hayes L, McCarthy K, Soudemire J, Schaub R, Goldman SJ. Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 1993; 81: 901-8.
82. Yang Y. Interleukin II: An overview. Stem Cells 1993; 11: 474-86.
83. Yonemura Y, Kawakita M, Masuda T, Fujimoto K, Takatsuki K. Effect of recombinant human interleukin-11 on rat mega-karyopoiesis and thrombopoiesis in vivo: Comparative study with interleukin-6. Br J Haematol 1993; 84: 16-23.
84. Nash RA, Seidel K, Storb R, Slichter S, Schuening FG, Appelbaum FR, Becker AB, Bolles L, Deeg HJ, Graham T, Hackman RC, Burstein SA. Effects of rhIL-11 on normal dogs and after sublethal radiation. Exp Hematol 1995; 23: 389-96.
85. Leonard JP, Quinto CM, Kozitza MK, Neben TY, Goldman SJ. Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. Blood 1994; 83: 1499-506.
86. Tepler I, Elias L, Smith JW, II, Hussein M, Rosen G, Chang AYC, Moore JO, Gordon MS, Kuca B, Beach KJ, Loewy JW, Garnick MB, Kaye JA. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607-14.
87. Gordon MS, McCaskill-Stevens WJ, Battiato LA, Loewy J, Loesch D, Breeden E, Hoffman R, Beach KJ, Kuca B, Kaye J, Sledge GW, Jr. Phase I trial of recombinant human interleukin-11 (Nuemega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87: 3615-24.
88. Metcalf D, Nicola NA, Gearing DP. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 1990; 76: 50-6.
89. Mayer P, Geissier K, Ward M, Metcalf D. Recombinant human leukemia inhibitory factor induces acute phase proteins and raises the blood platelet counts in nonhuman primates. Blood 1993; 81: 3226-33.
90. Farese AM, Myers LA, MacVittie TJ. Therapeutic efficacy of recombinant human leukemia inhibitory factor in a primate model of radiation-induced marrow aplasia. Blood 1994; 84: 3675-8.
91. Wallace PM, MacMaster JF, Rillema JR, Burstein SA, Shoyab M. Thrombocytopoietic properties of oncostatin M. Blood 1995; 86: 1310-5.
92. Leary AG, Ikebuchi K, Hirai Y, Wong GG, Clark SC, Ogawa M. Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1α. Blood 1988; 71: 1759-63.
93. Yonemura Y, Kawakita M, Masuda T, Fujimoto K, Kato K, Takatsuki K. Synergistic effects of interleukin 3 and interleukin 11 on murine megakaryopoiesis in serum-free culture. Exp Hematol 1992; 20: 1011-6.
94. Smith II JW, Longo DL, Alvord WG, Janik JE, Sharfman WH, Gause BL, Curti BD, Creekmore SP, Holmlund JT, Fenton RG, Sznol M, Miller LL, Shimizu M, Oppenheim JJ, Fiem SJ, Hursey JC, Powers GC, Urba WJ. The effect of treatment with interleukin-1α on platelet recovery after high-doe carboplatin. N Engl J Med 1993; 328: 756-61.
95. Williams DE, Morrissey PJ. Alterations in megakaryocyte and platelet compartments following in vivo IL-1β administration to normal mice. J Immunol 1989; 142: 4361-5.
96. Migliaccio G, Migliaccio AR, Adamson JW. In vitro differentiation and proliferation of human hematopoietic progenitors: The effects of interleukins 1 and 6 are indirectly mediated by production of granulocyte-macrophage colony-stimulating factor and interleukin 3. Exp Hematol 1991; 19: 3-10.
97. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
98. Hill RJ, Levin J. Regulators of thrombopoiesis: Their bio-chemistry and physiology. Blood Cells 1989; 15: 141-66.
99. Dessypris EN, Gleaton JH, Armstrong OL. Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro. Br J Haematol 1987; 65: 265-9.
100. Ishibashi T, Koziol J, Burstein SA. Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest 1987; 79: 286-9.
101. Fraser JK, Tan AS, Lin FK, Berridge MV. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol 1989; 17: 10-16.
102. Semenza GL, Traystman MD, Gearhart JD, Antonarakis SE. Polycythemia in transgenic mice expressing the human erythropoietin gene. Proc Natl Acad Sci USA 1989; 86: 2301-5.
103. Berridge MV, Fraser JK, Carter JM, Lin FK. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. Blood 1988; 72: 970-7.
104. Shikama Y, Ishibashi T, Kimura H, Kawaguchi M, Uchida T, Maruyama Y. Transient effect of erythropoietin on thrombocytopoiesis in vivo in mice. Exp Hematol 1992; 20: 216-22.
105. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-8.
106. Hatake K, Izumi T, Imagawa S, Ohta M, Miura Y. Macrophage colony-stimulating factor and platelet recovery after chemotherapy. Lancet 1993; 341: 963.
107. Weiner LM, Li W, Holmes M, Catalano RB, Dovnarsky M, Padavic K, Alpaugh RK. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon; toxicity, monocytosis, and clinical effects. Cancer Res 1994; 54: 4084-90.
108. Shimoda K, Okamura S, Harada N, Kondo S, Okamura T, Niho Y. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest 1993; 91: 1310-3.
109. Glaspy JA, Golde DW. Granulocyte colony-stimulating factor (G-CSF): Preclinical and clinical studies. Semin Oncol 1992; 19: 386-94.
110. Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, Horning SJ, Brown SL, Miller L, Blume KG. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1983; 81: 2031-5.
111. Brugger W, Birken R, Bertz H, Hecht T, Pressler K, Frisch J, Schulz G, Mertelsmann R, Kanz L. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br J Haematol 1993; 84: 402-7.
112. Grigg A, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM. Effect of peripheral blood progenitor cells mobilised by filgastim (G-CSF) on platelet recovery after high-dose chemotherapy. Bone Marrow Transplant 1993; 11: 23-9.
113. Brugger W, Frisch J, Schulz G, Pressler K, Mertelsmann R, Kanz L. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 1992; 10: 1452-9.
114. Ganser A, Lindemann A, Ottmann OG, Seipelt G, Hess U, Geissler G, Kanz L, Frisch J, Schulz G, Herrmann F, Mertelsmann R, Hoelzer D. Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: Results of a phase I study. Blood 1992; 79: 2583-91.
115. Naparstek E, Hardan Y, Ben-Shabar M, Nagler A, Or R, Mumcuoglu M, Weiss L, Samuel S, Slavin S. Enhanced marrow recovery by short preincubation of marrow allografts with human recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992; 80: 1673-8.
116. Farese AM, Williams DE, Seiler FR, MacVittie TJ. Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage colony-stimulating factor in a primate model of radiation-induced marrow aplasia. Blood 1993; 82: 3012-8.
117. Sullivan GW, Carper HT, Mandell GL. The effect of three human recombinant hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-3) on phagocytic oxidative activity. Blood 1993; 81: 1863-70.
118. Thompson CB, Jakubowski JA. The pathophysiology and clinical relevance of platelet heterogeneity. Blood 1988; 72: 1-8.
119. Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR. Platelet size and age determine platelet function independently. Blood 1984; 63: 1372-5.
120. Blajchman MA, Senyi AF, Hirsh J, Genton E, George JN. Hemostatic function, survival and membrane glycoprotein changes in young versus old rabbit platelets. J Clin Invest 1981; 68: 1289-94.
121. Peng JP, Friese P, Heilmann E, George JN, Burstein SA, Dale GL. Aged platelets have an impaired response to thrombin. Blood 1994; 83: 161-6.
122. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972; 187: 155-9.
123. Chen JC, Herceg-Harjacek L, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995; 86: 4054-62.
124. Kojima H, Hamazaki Y, Nagata Y, Todokoro K, Nagasawa T, Abe T. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemost 1995; 74: 1541-5.
125. Montrucchio G, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi G. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996; 87: 2762-8.
126. Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y, Handa M, Kato T, Miyazaki H, Shimosaka A, Ikeda Y. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996; 87: 4664-70.
127. Rodríguez-Liñares B, Watson SP. Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphotylation. Biochem J 1996; 316: 93-8.
128. c-cbl is present in human blood platelets and is differentially involved in signaling by thrombopoietin and thrombin. Blood 1996; 88: 1330-8.
129. Grabarek J, Groopman JE, Lyles YR, Jiang S, Bennett L, Zsebo K, Avraham H. Human kit ligand (stem cell factor) modulates platelet activation in vitro. J Biol Chem 1994; 269: 21718-24.
130. Avenarius HJ, Freund M, Deinhardt J, Poliwoda H. Effect of recombinant human granulocyte colony-stimulating factor on circulating platelets. Ann Hematol 1992; 65: 6-9.
131. Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K. Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor. Br J Haematol 1996; 94: 413-6.
132. Cook PP, Chen J, Ways DK. Interleukin-3 induces translocation and down-regulation of protein kinase C in human platelets. Biochem Biophys Res C ommun 1992; 185: 670-5.
133. Oleksowicz L, Mrowiec Z, Isaacs R, Dutcher J, Puszkin E. Morphologic and ultrastructural evidence for interleukin-6 induced platelet activation. Am J Hematol 1995; 48: 92-9.
134. Oleksowicz L, Mrowiec Z, Zuckerman D, Isaacs R, Dutcher J, Puszkin E. Platelet action induced by interleukin-6. Evidence for a mechanism involving arachidonic acid metabolism. Thromb Haemost 1994; 72: 302-8.
135. Heilmann E, Friese P, Anderson S, George JN, Hanson SR, Burstein SA, Dale GL. Biotinylated platelets: A new approach to the measurement of platelet life span. Br J Haematol 1993; 85: 729-35.
136. Peng JP, Friese P, George JN, Dale GL, Burstein SA. Alteration of platelet function in dogs mediated by interleukin-6. Blood 1994; 83: 398-403.
137. Peng JP, Friese P, Wolf RF, Harrison P, Downs T, Lok S, Dale GL, Burstein SA. Relative reactivity of platelets from thrombopoietin-and interleukin-6 treated dogs. Blood 1996; 87: 4158-63.
138. Dale GL, Friese P, Hynes LA, Burstein SA. Demonstration that thiazole-orange-positive platelets in the dog are less than 24 hours old. Blood 1995; 85: 1822-5.
139. Kaviani MD, Mason LE, Bree AG, Nagle SL, Schlerman FJ, Donnelly LH, Schaub RG, Zucker-Franklin D, Goldman SJ. Effects of recombinant human interleukin-11 on the activation and morphology of peripheral blood platelets and megakaryocytes in nonhuman primates. Blood 1996; 88(Suppl 1): 26a (Abstract).
140. Rabris R, Cordiano I, Randi ML, Casonato A, Montini G, Zacchello G, Girolami A. Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by haemodialysis. Pediatr Nephrol 1991; 5: 225-8.
141. Cases A, Escolar G, Reverter JC, Ordinas A, Pedret JL, Revert L, Castillo R. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992; 42: 668-72.
142. Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; 2: 1227-9.
143. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990; 300: 573-8.
144. Burstein SA, Peng J, Friese P, Wolf RF, Harrison P, Downs T, Hamilton K, Comp P, Dale GL. Cytokine-induced alteration of platelet and hemostatic function. Stem Cells 1996; 14(Suppl 1): 154-62.
145. Sironi M, Breviario F, Proscrpio P, Biondi A, Vecchi A, van Damme J, Dejana E, Mantovani A. IL-1 stimulates IL-6 production in endothelial cells. J Immunol 1989; 142: 549-53.
146. Zhang Y, Lin JX, Yip YK, Vilcek J. Stimulation of interleukin-6 mRNA levels by tumor necrosis factor and interleukin-1. Ann NY Acad Sci 1989; 557: 548-9.
147. Waring P, Wall D, Dauer R, Parkin D, Metcalf D. The effects of leukaemia inhibitory factor on platelet function. Br J Haematol 1993; 83: 80-7.
148. Ferroni P, Roselli M, Diodati A, Casciani C, Gazzaniga P. Effects on platelet function by human interferon-beta in carcinoma patients. Anticancer Res 1994; 14: 2779-84.
149. Wickenhauser C, Lorenzen J, Thiele J, Hillienhof A, Jungheim K, Schmitz B, Hansmann M-L, Fischer R. Secretion of cytokines (interleukins-1α, -3, and -6 and granulocyte-macrophage colony-stimulating factor) by normal human bone marrow megakaryocytes. Blood 1995; 85: 685-91.
150. Hawrylowicz CM, Howells GL, Feldmann M. Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med 1991; 174: 785-90.
151. Sedlmayr P, Blaschitz A, Wilders-Truschnig M, Tiran A, Dohr G. Platelets contain interleukin-1 alpha and beta which are detectable on the cell surface after activation. Scand J Immunol 1995; 42: 214.
152. Ross R. Platelet-derived growth factor. Lancet 1989; 1: 1179-82.
153. Massague J. The TGF-β family of growth and differentiation factors. Cell 1987; 49: 437-8.
154. Esmon CT. Cell mediated events that control blood coagulation and vascular injury. Annu Rev Cell Biol 1993; 9: 1-26.
155. Jaffe EA. Vascular function in hemostasis. In: Beutler E, Lichtman MA, Coller BS, Kipps TF eds. Williams Hematology. New York: McGraw-Hill, 1995: 1271-76.
156. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992; 6: 2591-9.
157. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70: 427-50.
158. Khew-Goodall Y, Butcher CM, Litwin MS, Newlands S, Korpelainen EI, Noack LM, Berndt MC, Lopez AF, Gamble JR, Vadas MA. Chronic expression of P-selectin on endothelial cells stimulated by the T-cell cytokine, interleukin-3. Blood 1996; 87: 1432-8.
159. Maruo N, Morita I, Shirao M, Murota SI. IL-6 increases endothelial permeability in vitro. Endocrinology 1992; 131: 710-4.
160. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271: 736-41.
161. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82: 1395-401.
162. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994; 91: 3974-8.
163. Burstein SA, Downs T, Friese P, Lynam S, Anderson S, Henthorn J, Epstein RB, Savage K. Thrombocytopoiesis in normal and sublethally irradiated dogs: Response to human interleukin-6. Blood 1992; 80: 420-8.
164. Harrison P, Downs T, Friese P, Wolf R, George JN, Burstein SA. Inhibition of the canine acute phase response by anti-gp130 monoclonal antibodies. Br J Haematol 1996; 95: 443-51.
165. Mestries JC, Kruithof EKO, Gascon MP, Herodin F, Agay D, Ythier A. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw 1994; 5: 275-81.
166. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk 1995; 2: 197-205.
167. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
168. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
169. Wakefield TW, Greenfield LJ, Rolfe MW, DeLucia III A, Strieter RM, Abrams GD, Kunkel SL, Esmon CT, Wrobleski SK, Kadell AM, Burdick MD, Taylor FB. Inflammatory and procoagulant mediator interactions in an experimental baboon model of venous thrombosis. Thromb Haemost 1993; 69: 164-72.
170. Robson SC, White NW, Aronson I, Woollgar R, Goodman H, Jacobs P. Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Br J Haematol 1996; 93: 943-9.
171. Van der Poll T, Levi M, Hack CE, Ten Cate H, Van Deventer SJH, Eerenberg AJM, De Groot ER, Jansen J, Gallati H, Büller HR, Ten Cate JW, Aarden LA. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-9.
172. Hendrix C, Anne J, Joris B, Van Aerschot A, Herdewijn P. Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 6 mRNA. Biochem J 1996; 314: 655-61.
173. Yanofsky SD, Baldwin DN, Butler JH, Holden FR, Jacobs JW, Balasubramanian P, Chinn JP, Cwiria SE, Peters-Bhatt E, Whitehorn EA, Tate EH, Akeson A, Bowlin TL, Dower WJ, Barrett RW. High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. proc Natl Acad Sci USA 1996; 93: 7381-6.
174. de Hon FD, Ehlers M, Rose-John S, Ebeling SB, Bos HK, Aarden LA, Brakenhoff JPJ. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells. J Exp Med 1995; 180: 2395-400.
175. Salvati AL, Lahm A, Paonessa G, Ciliberto G, Toniatti C: Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor α mutated in the predicted gp130-binding interface. J Biol Chem 1995; 270: 12242-9.
176. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550-2.
177. Beutler E. Platelet transfusions: The 20.000/μL trigger. Blood 1993; 81: 1411-3.
178. Nagler A, Eldor A, Naparstek E, Mumcuoglu M, Slavin S, Deutsch VR. Ex vivo expansion of megakaryocyte precursors by preincubation of marrow allografts with interleukin-3 and granulocyte-macrophage colony-stimulating factor in vitro. Exp Hematol 1995; 23: 1268-74.
179. Moore MAS. Expansion of myeloid stem cells in culture. Semin Hematol 1995; 32: 183-200.